Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Quarterly Letrozole SIE vs Daily Oral Letrozole in Post-Menopausal Women With HR+ Early Breast Cancer
NCT07401381Phase 1Recruiting
- Sponsor
- Laboratorios Farmacéuticos ROVI
- Start
- Jun 2026
- Primary completion
- May 2028
- Modality
- Orthosteric Ligands
- Countries
- 3
01
Overview
Phase 1, randomised, open-label trial of letrozole in breast cancer (2 arms), sponsored by Laboratorios Farmacéuticos ROVI. Primary endpoint: Area under the concentration-time curve within a dosing interval at Steady-State at Day 281. Started Jun 2026; status: recruiting.
02
Drugs
letrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07401381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07401381.